Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581 · see citing works

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574 · see citing works

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 519 · see citing works

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Kobayashi, S., Canepa, H. M., Bailey, A. S., Nakayama, S., Yamaguchi, N., Goldstein, M. A., Huberman, M. S., & Costa, D. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182781e35 · Cited by 213 · see citing works

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206 · see citing works

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Conklin, C. M. J., Craddock, K. J., Have, C. L., Laskin, J. J., Couture, C., & Ionescu, D. N. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318274a83e · Cited by 192 · see citing works

Assessing<i>EGFR</i>Mutations

(2006) · New England Journal of Medicine · doi:10.1056/nejmc052564 · Cited by 189 · see citing works

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations

Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178 · see citing works

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

Sun, J., Ahn, M., Choi, Y., Ahn, J. S., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.023 · Cited by 118 · see citing works

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

Won, Y., Han, J., Lee, G. K., Park, S.-Y., Lim, K. Y., Yoon, K., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200169 · Cited by 74 · see citing works

Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma

Errihani, H. H., Inrhaoun, H., Boukir, A., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f6b4a · Cited by 45 · see citing works

Second-Line Therapy for Advanced NSCLC

Weiss, J. M., & Stinchcombe, T. E. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0096 · Cited by 45 · see citing works

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma

Kim, H. R., Cho, B. C., Shim, H. S., Lim, S. M., Kim, S. I., Chang, J., Kim, D. J., & Kim, J. H. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.011 · Cited by 40 · see citing works

Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.

Liu, Y., Wu, B., Zhong, H., Hui, P., & Fang, W. (2013) · Europe PMC (PubMed Central) · Cited by 33 · see citing works

Encouragement to Submit Data of Clinical Response to EGFR-TKIs in Patients With Uncommon EGFR Mutations

Yatabe, Y., Pao, W. J., & Jett, J. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318251980b · Cited by 20 · see citing works

Third-line therapy in advanced non-small cell lung cancer.

Geng, Z. Y., Jiao, S., Liu, S. C., et al. (2014) · PubMed · Cited by 11 · see citing works

First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay

Hirsch, F. R., Dziadziuszko, R., Varella‐Garcia, M., Franklin, W. A., Gandara, D. R., & Bunn, P. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e922 · Cited by 9 · see citing works

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

Frega, S., Lorenzi, M., Fassan, M., Indraccolo, S., Calabrese, F., Favaretto, A., Bonanno, L., Polo, V., Zago, G., Lunardi, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15945 · Cited by 17 · see citing works

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy

Endo, K., Sasaki, H., Yano, M., Kobayashi, Y., Yukiue, H., Haneda, H., Suzuki, E., Kawano, O., & Fujii, Y. (2006) · Oncology Reports · doi:10.3892/or.16.3.533 · Cited by 37 · see citing works

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0462 · Cited by 584 · see citing works

Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

Uruga, H., Kishi, K., Fujii, T., Beika, Y., Enomoto, T., Takaya, H., Miyamoto, A., Morokawa, N., Kurosaki, A., & Yoshimura, K. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2531 · Cited by 34 · see citing works

Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor

Ogasawara, M., Nakamura, Y., Morikawa, N., Nitanai, H., Moriguchi, S., Chiba, R., Saito, H., Ohta, M., Tanita, T., Sugai, T., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3021-y · Cited by 8 · see citing works

PD-149 Epidermal growth factor receptor (EGFR)-activating mutations(mut) and response to gefitinib in lung adenocarcinomas

Morán, T., Castellanos, D., Gómez, C. G., et al. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)80482-9